DH
David Hoang Deutsche Bank Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Sarepta Therapeutics
SRPT
$1.96B
| $18.71 | $12 |
36%
downside
| Sell | 22 days ago |
|
2
Harmony Biosciences
HRMY
$2.07B
| $35.99 | $55 |
53%
upside
| Buy | 1 month ago |
|
3
Acadia Pharmaceuticals
ACAD
$4.26B
| $25.26 | $35 |
39%
upside
| Buy | 3 months ago |
|
4
Alkermes
ALKS
$4.94B
| $29.94 | $52 |
74%
upside
| Buy | 5 months ago |
|
5
Xenon Pharmaceuticals
XENE
$3.02B
| $39.21 | $67 |
71%
upside
| Buy | 6 months ago |
|
6
Praxis Precision Medicines
PRAX
$986M
| $46.85 | $111 |
137%
upside
| Buy | 6 months ago |
|
7
Denali Therapeutics
DNLI
$2.26B
| $15.43 | $31 |
101%
upside
| Buy | 6 months ago |
|
8
Biohaven
BHVN
$1.68B
| $15.87 | $65 |
310%
upside
| Buy | 6 months ago |
|
9
Axsome Therapeutics
AXSM
$6.25B
| $125.17 | $176 |
41%
upside
| Buy | 6 months ago |
|
|
AVDL
10
Avadel Pharmaceuticals
AVDL
$1.53B
| $15.76 | $12 |
24%
downside
| Buy | 6 months ago |
|
|
11
Acadia Pharmaceuticals
ACAD
$4.26B
| $25.26 | $23 |
9%
downside
| Buy | 1 year ago |
|
|
12
Sarepta Therapeutics
SRPT
$1.96B
| $18.71 | $160 |
755%
upside
| Neutral | 1 year ago |
|
13
Neurocrine Biosciences
NBIX
$14.3B
| $144.10 | $158 |
10%
upside
| Neutral | 1 year ago |
|
|
14
Denali Therapeutics
DNLI
$2.26B
| $15.43 | $32 |
107%
upside
| Buy | 1 year ago |
|
|
15
Harmony Biosciences
HRMY
$2.07B
| $35.99 | $48 |
33%
upside
| Buy | 1 year ago |
|
|
16
Xenon Pharmaceuticals
XENE
$3.02B
| $39.21 | $60 |
53%
upside
| Buy | 1 year ago |
|
|
17
Axsome Therapeutics
AXSM
$6.25B
| $125.17 | $125 |
0%
downside
| Buy | 1 year ago |
|
18
Solid Biosciences
SLDB
$428M
| $5.50 | $16 |
191%
upside
| Buy | 1 year ago |
|
19
Alnylam Pharmaceuticals
ALNY
$59.2B
| $452 | $220 |
51%
downside
| Neutral | 2 years ago |
|
20
Arrowhead Research
ARWR
$4.02B
| $29.07 | $80 |
175%
upside
| Outperform | 2 years ago |
|
|
21
Sarepta Therapeutics
SRPT
$1.96B
| $18.71 | $185 |
889%
upside
| Outperform | 2 years ago |
|
22
Gossamer Bio
GOSS
$668M
| $2.94 | $3 |
2%
upside
| Neutral | 2 years ago |
|